MedKoo Cat#: 317887 | Name: Fluocinolone Acetonide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fluocinolone acetonide is a corticosteroid primarily used in dermatology to reduce skin inflammation and relieve itching. It is a synthetic hydrocortisone derivative. The fluorine substitution at position 9 in the steroid nucleus greatly enhances its activity. A typical dosage strength used in dermatology is 0.01–0.025%. Fluocinolone acetonide was also found to strongly potentiate TGF-β-associated chondrogenesis of bone marrow mesenchymal stem/progenitor cells, by increasing the levels of collagen type II by more than 100 fold compared to the widely used dexamethasone.

Chemical Structure

Fluocinolone Acetonide
Fluocinolone Acetonide
CAS#67-73-2

Theoretical Analysis

MedKoo Cat#: 317887

Name: Fluocinolone Acetonide

CAS#: 67-73-2

Chemical Formula: C24H30F2O6

Exact Mass: 452.2010

Molecular Weight: 452.49

Elemental Analysis: C, 63.70; H, 6.68; F, 8.40; O, 21.22

Price and Availability

Size Price Availability Quantity
500mg USD 350.00 2 Weeks
1g USD 600.00 2 Weeks
2g USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Fluocinolone Acetonide, Synandone, Flucinar, Fluonid, Jellin, Sinalar; Fluocinolone 16,17-acetonide; NSC 92339; NSC92339; NSC-92339
IUPAC/Chemical Name
(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
InChi Key
FEBLZLNTKCEFIT-VSXGLTOVSA-N
InChi Code
InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1
SMILES Code
O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@]4(C)[C@]5(C(CO)=O)OC(C)(C)O[C@]5([H])C[C@@]4([H])[C@]3([H])C[C@H](F)C2=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 452.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Soubrane G, Behar-Cohen F. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema]. J Fr Ophtalmol. 2015 Feb;38(2):159-67. doi: 10.1016/j.jfo.2014.09.007. Epub 2015 Jan 16. Review. French. PubMed PMID: 25601517. 2: Ciulla TA, Harris A, McIntyre N, Jonescu-Cuypers C. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. Expert Opin Pharmacother. 2014 May;15(7):953-9. doi: 10.1517/14656566.2014.896899. Epub 2014 Mar 24. Review. PubMed PMID: 24661081. 3: Messenger WB, Beardsley RM, Flaxel CJ. Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema. Drug Des Devel Ther. 2013 May 24;7:425-34. doi: 10.2147/DDDT.S44427. Print 2013. Review. PubMed PMID: 23737661; PubMed Central PMCID: PMC3668088. 4: Sanford M. Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema. Drugs. 2013 Feb;73(2):187-93. doi: 10.1007/s40265-013-0010-x. Review. PubMed PMID: 23335133. 5: Schwartz SG, Flynn HW Jr. Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol. 2011 Mar 1;12(3):347-51. Review. PubMed PMID: 20939799. 6: Fluocinolone acetonide ophthalmic--Bausch & Lomb: fluocinolone acetonide Envision TD implant. Drugs R D. 2005;6(2):116-9. Review. PubMed PMID: 15777105. 7: Mazurkiewicz W. [Fluocinolone acetonide in dermatological practice]. Przegl Dermatol. 1975 Jan-Feb;62(1):121-5. Review. Polish. PubMed PMID: 1089265. 8: Brumm MV, Nguyen QD. Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management. Int J Nanomedicine. 2007;2(1):55-64. Review. PubMed PMID: 17722513; PubMed Central PMCID: PMC2673825.